Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Shalvata Mental Health Center.
Recruitment status was  Recruiting
Information provided by:
Shalvata Mental Health Center
ClinicalTrials.gov Identifier:
First received: October 11, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.

Condition Intervention Phase
Marijuana Abuse
Device: H-Coil deep TMS
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shalvata Mental Health Center:


Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and Female, aged 21-70 years, who meet DSM-IV TR diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study.

Exclusion Criteria:

  • History of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to DSM-IV TR criteria.
  • Hamilton depression scale rated 25 and above (moderate to severe depression)
  • Current alcohol or other substance abuse or dependence
  • Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
  • History of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery.
  • Severe somatic co-morbidity
  • History of seizures Cardiac pace maker or other electronic implants Pregnancy and lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543036

Contact: Ziv Carmel, M.D. +972-9-7478570 zivca@clalit.org.il

Shalvata Mental Health Center Recruiting
Hod-HaSharon, Israel, 45100
Contact: Ziv Carmel, M.D    +972-9-7478570    zivca@clalit.org.il   
Principal Investigator: Ziv Carmel, M.D         
Sponsors and Collaborators
Shalvata Mental Health Center
Principal Investigator: Ziv Carmel, M.D Shalvata MHC affiliated to Tel-Aviv universtiy, Sackler school of medicine
Principal Investigator: Abraham Zangen, Ph.D. Weizmann Institute, Rehovot, Israel
  More Information

ClinicalTrials.gov Identifier: NCT00543036     History of Changes
Other Study ID Numbers: SH 30107 
Study First Received: October 11, 2007
Last Updated: October 11, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Shalvata Mental Health Center:

Additional relevant MeSH terms:
Marijuana Abuse
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders

ClinicalTrials.gov processed this record on May 25, 2016